ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer.

Paula I Gonzalez-Ericsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.